Item 1.01. Entry into a Material
Definitive Agreement.
On April 5, 2020, Regeneron Pharmaceuticals,
Inc. (“Regeneron” or the “Company”) and Sanofi Biotechnology SAS (“Sanofi”)
entered into the Third Amendment to Amended and Restated License and Collaboration Agreement (the “Third Amendment”),
which amends the Amended and Restated License and Collaboration Agreement, dated as of November 10, 2009, by and between the
Company and Sanofi (as successor in interest to Aventis Pharmaceuticals Inc. and Sanofi-Aventis Amérique Du Nord), as amended
(the “Antibody LCA”). The Antibody LCA provides for the development, manufacture, and commercialization of certain
antibody products, including, prior to April 1, 2020 (and prior to giving effect to the Third Amendment), Praluent®
(alirocumab). On April 5, 2020, the Company and Sanofi also entered into the Praluent Cross License & Commercialization Agreement
(the “Praluent Agreement” and, together with the Third Amendment, collectively, the “Agreements”).
The Agreements are each effective from and after April 1, 2020. As described in greater detail below, the Agreements together effect
the previously announced restructuring of the parties’ antibody collaboration in respect of Praluent.
Third Amendment. Under the Third Amendment,
Sanofi and the Company amended the Antibody LCA, among other things, to remove Praluent from the Antibody LCA such that (a) effective
April 1, 2020, the Antibody LCA no longer governs the development, manufacture, or commercialization of Praluent and (b) the quarterly
period ended March 31, 2020 is the last quarter for which Sanofi and the Company will share profits and losses for Praluent under
the Antibody LCA. Notwithstanding the foregoing, net product sales of Praluent outside the United States will continue to be taken
into account to determine (x) each party’s percentage share of profits and losses outside the United States from the products
that continue, from and after April 1, 2020, to be governed by the Antibody LCA and (y) the milestones applicable to net product
sales outside the United States under the Antibody LCA.
Praluent Agreement. Under the Praluent
Agreement, effective April 1, 2020, the Company, at its sole cost, is solely responsible for the development and commercialization
of Praluent in the United States, and Sanofi, at its sole cost, is solely responsible for the development and commercialization
of Praluent outside of the United States. Each of the Company and Sanofi will obtain an exclusive license under certain intellectual
property rights of the other party to commercialize Praluent in the United States and outside the United States, respectively.
Because before April 1, 2020 Sanofi was, under the Antibody LCA, responsible for commercializing Praluent in the United States,
Sanofi will transfer to the Company certain assets relating to the commercialization of Praluent in the United States.
Sanofi will pay the Company a 5% royalty on
Sanofi’s net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties
on the Company’s net product sales of Praluent in the United States.
Although each party will be responsible for
manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for
a certain transitional period (a) the Company will continue to supply drug substance to Sanofi and (b) Sanofi will continue to
supply finished product to Regeneron.
With respect to any intellectual property or
product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi
each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United
States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020.
The parties will each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. If Sanofi
is obligated to pay any third-party royalties on Praluent sales outside the United States after April 1, 2020 as a result of certain
patent litigation proceedings, then Sanofi will have the right to set off 50% of such third-party royalty payments against up to
50% of any Praluent royalty payment owed to Regeneron.
The foregoing description of the Third
Amendment and the Praluent Agreement is qualified in its entirety by reference to the full text of the Third Amendment and the
Praluent Agreement, respectively, a copy of each of which will be filed with the U.S. Securities and Exchange Commission as an
exhibit to the Quarterly Report on Form 10-Q to be filed by the Company for the quarterly period ending June 30, 2020.